entertainment news

New Delhi [India], September 26 (ANI): The Delhi High Court has observed that while satire and political criticism are part of free speech, obscene and sexually suggestive attacks cannot be justified under its garb.

Justice Amit Bansal made the remarks while passing an ad-interim injunction in favour of BJP spokesperson and Senior Advocate Gaurav Bhatia in his plea against allegedly defamatory and morphed posts circulated after a viral TV debate clip.

The Court stated that public figures like Bhatia must meet a higher threshold for defamation, as their actions are subject to greater scrutiny and criticism. However, Justice Bansal clarified that dignity cannot be attacked with vulgar or morphed content.

The Court held that while some of the impugned posts appeared satirical or hyperbolic and therefore required the defendants’ response before any restraint could be imposed, immediate action was warranted against content that was explicit and offensive.

Accordingly, it directed the Samajwadi Party Media Cell and another defendant to remove specific URLs within 24 hours, failing which X (formerly Twitter) must take them down within 72 hours.

It also ordered the immediate removal of a morphed post by user @VishPatel644653 captioned “Coming out of a Vish Patel Neha Twitter Gaurav Bhatia coming out of weight Rape,” restrained all defendants from circulating explicit, obscene or sexually suggestive material about Bhatia, and directed X to disclose subscriber information of several defendants and the said user within a week.

The matter is scheduled to be taken up next on October 30, 2025, before the Joint Registrar and on November 19, 2025, before the Court. (ANI)

Source

The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.

Pune (Maharashtra) [India], September 26 (ANI): Maharashtra Deputy Chief Minister Ajit Pawar on Friday said that India has to make its own decisions for the benefit of people here, just as the US does for itself, adding that the use of swadeshi goods needs to be increased.

The remarks come after the Trump administration decided to impose a 100 per cent tariff on branded and patented pharmaceutical products by the US on India beginning October 1.

Speaking to reporters here, Pawar stated that it was India’s responsibility to respond to decisions concerning the country in a dignified manner and to solely increase the use of swadeshi goods.

“Alright, we can make decisions about our own country, just as they are making decisions for theirs. If Trump or any other country’s leader has made a decision, it is because the people in that country have elected them, and thus they are exercising their right to make such decisions. Our responsibility is to respond to any decision concerning our country in a dignified manner and to increase the use of products made in our own country (swadeshi goods),” he said.

Remembering Mahatma Gandhi’s call for Swadeshi, Pawar said, “Now it has been reiterated by India’s Prime Minister Narendra Modi. It has been 75 years since our country gained independence, and now many items in our country are available in even higher quality than those imported from abroad. In fact, there are many things, such as clothes and others, that are manufactured here, but they sell them abroad by labelling them as made in their country.”

The Indian pharmaceutical sector supplies over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 per cent of all medicines in the UK. India’s annual drug and pharmaceutical exports touched a record USD 30 billion in FY25, bolstered by a 31 per cent year-on-year surge in March.

According to a government release, drug and pharmaceutical exports increased by 6.94 per cent from USD 2.35 billion in August 2024 to USD 2.51 billion in August 2025 alone.

According to a separate government report, India’s pharmaceutical industry is a global powerhouse, ranking third in the world by volume and 14th in terms of production value. It supplies over 50 per cent of global vaccine demand and nearly 40 per cent of generics to the US. The industry is projected to grow to USD 130 billion by 2030 and a USD 450 billion market by 2047. (ANI)

Source

The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.